2. Flow chart

Screening procedures

1. Approval of EC and RA
2. Patient signs informed consent
3. Please send
   - samples for immunophenotyping: 10 ml + 3,7 ml EDTA Blood (Cologne) and
   - samples for SNP Testing: 2 x 3,7 ml Heparinised Blood (Cologne) and
   - samples for cytogenetics: 20 – 40 ml Heparinised Blood (Ulm)
   - samples for MRD: 10 ml EDTA Blood, 10 ml Heparinised Blood (Kiel)
   - samples for Serum Parameters: 5 ml Serum (Munich)
4. If CLL is confirmed and patient has no 17p deletion please send baseline assessments and registration forms

Registration and Randomisation

Start of Treatment within 14 days after Randomisation

FCR Arm (n=275) ↔ **BR Arm (n=275)**

↓ **FCR Cycles 1-3** | ↓ **BR Cycles 1-3**

↓ **Interim Staging Before Cycle 4** ↓

All patients: MRD Testing (Kiel): 10 ml EDTA Blood, 10 ml Heparinised Blood

↓ **FCR Cycles 4-6** | ↓ **BR Cycles 4-6**

↓ **Initial Response Assessment 1 Month (± 7days) after *Beginning of* Last Cycle** ↓

Final Staging 2 Months (+ 28 days) after Initial Response Assessment

All patients: MRD Testing (Kiel): 10 ml EDTA Blood, 10 ml Heparinised Blood
Patients in clinical CR: BM-biopsy: Biopsy in KGF solution (Kiel)
BM-MRD: 5 rml Heparin-Bone marrow (Kiel)

↓

Follow-Up Every 3 Months (± 14 days) until 2 years after Final Staging

Patients with CR 12 and 18 months after Final Staging:
MRD Testing (Kiel): 10 ml EDTA Blood, 10 ml Heparinised Blood

All patients with Relapse Cytogenetic Testing (Ulm): 20-40 ml Heparinised Blood (only once)

↓

Follow-Up Every 6 Months (± 1 month) until 5 years after Final Staging

All patients with Relapse Cytogenetic Testing (Ulm) : 20-40 ml Heparinised Blood (only once)

↓

Annual Follow-Up‘s until January 2018

All patients with Relapse Cytogenetic Testing (Ulm): 20-40 ml Heparinised Blood (only once)

↓

Observational Study Protocol CLL10b with Annual Follow-Up‘s

All patients with Relapse Cytogenetic Testing (Ulm): 20-40 ml Heparinised Blood (only once)